4 ‐bp insertion/deletion (rs3783553) polymorphism within the 3'UTR of IL1A contributes to the risk of prostate cancer in a sample of Iranian Population

In conclusion, our findings proposed an association between IL1A 4‐bp ins/del polymorphism and PCa risk. Additional studies with enlarged sample size and diverse ethnicities are required to validate our finding. This article is protected by copyright. All rights reserved
Source: Journal of Cellular Biochemistry - Category: Biochemistry Authors: Tags: Article Source Type: research

Related Links:

Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Impact of RNA‑binding motif 3 expression on the whole transcriptome of prostate cancer cells: An RNA sequencing study. Oncol Rep. 2018 Aug 01;: Authors: Dong Q, Lv C, Zhang G, Yu Z, Kong C, Fu C, Zeng Y Abstract RNA‑binding motif 3 (RBM3) is a cold‑shock protein that has been previously shown to attenuate cancer stem cell‑like features in prostate cancer (PCa) cells. However, the mechanism underlying RBM3 regulation in PCa cells is largely unknown. The present study investigated the impact of RBM3 expression on the whole transcriptome of PCa cells using high‑throughput RNA sequencing (RNA‑s...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Zinc enhances chemosensitivity to paclitaxel in PC‑3 prostate cancer cells. Oncol Rep. 2018 Aug 02;: Authors: Zhang P, Li Y, Tang X, Guo R, Li J, Chen YY, Guo H, Su J, Sun L, Liu Y Abstract Paclitaxel‑based chemotherapy is a promising approach for prostate cancer treatment. However, single‑drug chemotherapy is associated with an increased risk of drug resistance. Therefore, novel combination chemotherapy regimens are a popular topic of research. Zinc participates in the regulation of apoptosis, for example in the form of Zn2+ and via zinc‑dependent enzymes. Zinc can either induce or suppress ap...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Correlation between DEC1/DEC2 and epithelial‑mesenchymal transition in human prostate cancer PC‑3 cells. Mol Med Rep. 2018 Aug 09;: Authors: Liu Q, Wu Y, Seino H, Haga T, Yoshizawa T, Morohashi S, Kijima H Abstract Differentiated embryonic chondrocyte (DEC) genes have been reported to be involved in the regulation of mammalian circadian rhythms, differentiation, apoptosis, the response to hypoxia and epithelial‑mesenchymal transition (EMT). Activation of transforming growth factor (TGF)‑β signaling is known to promote EMT for the development of metastatic castration‑resistant prostate ca...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
In conclusion, PYGB silencing suppressed the growth and promoted the apoptosis of prostate cancer cells by affecting the NF‑κB/Nrf2 signaling pathway. The present study provided evidence that may lead to the development of a potential therapeutic strategy for prostate cancer. PMID: 30106110 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Genomics and Health Disparities Lecture Series John Carpten, PhD is Professor and Chair for the Department of Translational Genomics. His training and professional experiences include postdoctoral training at the National Human Genome Research Institute/NIH, and serving as Deputy Director of Research at the Translational Genomics Research Institute (TGen). Dr. Carpten ’ cancer research program spans multiple disciplines including germline genetics for disease risk and predisposition, somatic cancer genomics, health disparities research, cell biology, functional genomics, and precision medicine. The primary focus of h...
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video
This article focuses on apalutamide, a next-generation nonsteroidal antiandrogen, with current literature queried in PubMed/Medline. A narrative review strategy describes studies from engineering of the compound through to a 5-year outlook. Expert commentary: In the phase III SPARTAN study, apalutamide significantly improved metastasis-free survival in patients with nonmetastatic castration-resistant prostate cancer - the first treatment approved by the US Food and Drug Administration for this indication. Phase III studies are under way to determine the clinical benefit of apalutamide in other disease states. Given the mul...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Chem. Commun., 2018, Advance Article DOI: 10.1039/C8CC05136D, CommunicationShuyan Yang, Defan Yao, Yanshu Wang, Weitao Yang, Bingbo Zhang, Dengbin Wang A peptide-modified gold nanoparticle was developed for tumour-targeted therapy. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research
Conditions:   Prostate Cancer;   Benign Prostatic Hypertrophy;   Bladder Stones;   Kidney Stones Intervention:   Diagnostic Test: NV-VPAC1 PCa Urine Diagnostic Test Sponsors:   Intermountain Health Care, Inc.;   NuView Diagnostics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Prostate Cancer;   Oligometastasis Interventions:   Drug: IADT;   Combination Product: IADT + radiotherapy Sponsors:   Institut Cancerologie de l'Ouest;   Direction Générale de l'Offre de Soins;   Astellas Pharma Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biochemistry | Cancer | Cancer & Oncology | Iran Health | Prostate Cancer | Study